The Conversation (0)
Brainsway (TASE:BRIN), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s financial results for the fourth quarter and year ended December 31, 2017, and provided a corporate update. As quoted in the press release: “2017 was a record-setting year for us after the adoption of our new business model in …
Brainsway (TASE:BRIN), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s financial results for the fourth quarter and year ended December 31, 2017, and provided a corporate update.
As quoted in the press release:
“2017 was a record-setting year for us after the adoption of our new business model in the first quarter of 2017,” said Yaacov Michlin, Chief Executive Officer of Brainsway. “We adopted a business model focusing on leasing our Deep Transcranial Magnetic Stimulation (Deep TMS) systems to customers, which continues to resonate well in the marketplace. Accordingly, our fourth quarter 2017 revenues of $3.6 million were up 68% over the first quarter of 2017. We have enjoyed steady growth in both leases and in sales of our systems throughout 2017.”
Latest News
Outlook Reports world
Featured Medical Device Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES